GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development
June 13, 2022 09:00 ET
|
GeoVax, Inc.
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at BIO International Convention 2022
June 07, 2022 09:00 ET
|
GeoVax, Inc.
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
May 25, 2022 13:47 ET
|
GeoVax, Inc.
Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
May 24, 2022 09:00 ET
|
GeoVax, Inc.
Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Upcoming Presentations at Scientific Conferences
May 04, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
April 27, 2022 16:00 ET
|
GeoVax, Inc.
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a...
GeoVax Announces Issuance of Malaria Vaccine Patent
April 26, 2022 09:00 ET
|
GeoVax, Inc.
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update
April 19, 2022 09:00 ET
|
GeoVax, Inc.
Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
April 18, 2022 17:52 ET
|
GeoVax, Inc.
Singapore, April 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--In a release issued under the same headline on Monday, April 18th at 1:55 ET by GeoVax, Inc., please note that the release was...
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress
April 12, 2022 09:00 ET
|
GeoVax, Inc.
Company’s COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100%...